Edition:
United States

Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

73.00EUR
10:53am EST
Change (% chg)

€1.13 (+1.58%)
Prev Close
€71.86
Open
€73.11
Day's High
€73.11
Day's Low
€72.67
Volume
1,054
Avg. Vol
1,925
52-wk High
€76.57
52-wk Low
€59.00

LLY.F

Chart for LLY.F

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)
No analyst recommendations are available for LLY.F.

Overall

No Ratios Available.

Financials

  LLY.F Industry Sector
P/E (TTM): -- 29.93 30.76
EPS (TTM): -- -- --
ROI: -- 15.46 14.89
ROE: -- 16.64 16.30

BRIEF-Colucid Pharmaceuticals says termination fee of $34 mln to be payable to Eli Lilly upon termination

* Colucid Pharmaceuticals - upon termination of deal under specified circumstances, co will be required to pay Eli Lilly termination fee of $34 million Source text (http://bit.ly/2jKbOWp) Further company coverage:

Jan 18 2017

US STOCKS-Wall St falls before earnings and on U.S. policy uncertainty

* Financials off with bond yields day before big banks' 4th-qtr reports

Jan 12 2017

BRIEF-U.S. appeals court rejects Teva appeal in Lilly patent case over Alimta

Jan 12 U.S. Appeals Court rules for Eli Lilly and against Teva Pharmaceutical in Alimta patent case -- court ruling

Jan 12 2017

Halozyme's pancreatic cancer drug succeeds in mid-stage trial

Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.

Jan 05 2017

Trump's corporate tax holiday could spur pharma M&A

U.S. President-elect Donald Trump's plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth.

Dec 06 2016

US STOCKS-S&P 500 dips with healthcare shares, Dow edges up ahead of holiday

* Dow up 0.1 pct, S&P down 0.1 pct, Nasdaq down 0.3 pct (Updates to late afternoon, adds dateline)

Nov 23 2016

BRIEF-Eli Lilly and CO incoming CEO David Ricks on CNBC - Amyloid Hypothesis should be continued to be studied in reference to its Alzheimer's drug

* Eli Lilly and CO incoming CEO David Ricks on CNBC - Amyloid Hypothesis should be continued to be studied in reference to its Alzheimer's drug

Nov 23 2016

BRIEF-Paulson & Co cuts share stake in Pfizer, raises share stake in Facebook

* Paulson & Co Inc raises share stake in Facebook Inc by 47.3 percent to 212,700 Class A shares

Nov 14 2016

BRIEF-Eli lilly and Incyte says Baricitinib treatment show improvements in rheumatoid arthritis symptoms in phase 3

* Eli lilly -new analyses of phase 3 trials show improvements in rheumatoid arthritis symptoms following treatment with Baricitinib Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Eli Lilly and Co says new data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes

* New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo

Nov 02 2016

Earnings vs. Estimates